Please login to the form below

Not currently logged in
Email:
Password:

Abbott sues J&J over Simponi

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira

Abbott laboratories has sued Johnson & Johnson over its drug Simponi, stating that preparations to market the drug infringe a patent issued for Humira.

Abbott's Humira (adalimumab), which treats rheumatoid arthritis, was issued a patent in 2007. Johnson & Johnson's Centocor unit plans to introduce golimumab, a new and competing drug for the crippling disease under the brand name Simponi.

Abbott is seeking cash compensation and an order to prevent further use of its invention by Johnson & Johnson.

Scott Stoffell, Abbott's spokesperson explained: "We're not asking the court to prevent the launch of Simponi. Abbott has no plans to file for a preliminary injunction or a temporary restraining order."

In response, Brian Kenney of Johnson & Johnson's Centocor unit said: "We are currently reviewing the complaint and will vigorously contest it… We believe we have rights to all of the intellectual property we need to market Simponi."

Johnson & Johnson received approval from the Food and Drug Administration (FDA) to market the anti-TNF-alpha therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009. The drug, to be co-marketed outside the US by Schering-Plough, will compete with Humira and Amgen's Enbrel.

5th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics